Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › SLIMMER-UP-SWITCH (interim)

SLIMMER-UP-SWITCH (interim)

Ecnoglutide · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Ecnoglutide
Population
obesity
Phase
2
Participants
163
Duration
20 weeks

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
2.4 mg vs semaglutide 2.4 mg: weight -9.5 %obesity china20163——−12.8 %
estimand not specified
———————press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (1)
  • 2.4 mg · weight_unsp · press release
    the least-squares mean percentage change in body weight from baseline was -12.8% in the ecnoglutide group and -9.5% in the semaglutide group

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: SLIMMER-UP-SWITCH (interim). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/slimmer-up-switch/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.